The Star · 28 Sep, 23:04 · Business briefing

UK risks missing out on biosimilar windfall

Recent reporting highlights that the United Kingdom faces significant financial risks by failing to capitalise on the biosimilar market.

What it means for you ↓ Courses for this story

26%average salary uplift after a professional certificate

2.7xfaster promotion for certified professionals

71%of leaders prefer candidates who upskill continuously

20days to your first credential

The briefing

The story
in brief.

What happened, who it affects, and why it landed on our intelligence desk — in plain English, sixty seconds or less.

Recent reporting highlights that the United Kingdom faces significant financial risks by failing to capitalise on the biosimilar market. Biosimilars are biological medicines highly similar to already approved reference products. Despite their potential to reduce healthcare costs and increase access to treatment, regulatory and structural barriers may prevent the UK from realising these economic benefits. The analysis suggests that without strategic intervention, the nation could miss a substantial opportunity to alleviate pressure on the NHS and stimulate domestic pharmaceutical innovation. This development underscores the critical need for policy alignment and industry readiness to ensure the UK remains competitive in the global biotechnology sector.

Employer demand for Healthcare Management skills — indexed growth since 2019
Indicative index of skill mentions in professional job postings for the field this story moves (2019 = 1)

Your move

What this means
for your career.

Every headline redistributes opportunity. Here is who this one rewards — and how to be on the right side of it.

This shift directly impacts your career trajectory in the pharmaceutical and healthcare sectors. Professionals in regulatory affairs, health economics, and strategic management will see increased demand. You must understand how biosimilars disrupt traditional pricing models and supply chains. Focus on developing expertise in market access strategies and regulatory compliance specific to biological products. If you work in healthcare management, prioritise learning about cost-benefit analysis for new therapies. Smart professionals will upskill in data analytics to evaluate clinical outcomes and economic impact. Consider specialising in biosimilar lifecycle management or health technology assessment. This is not just a niche trend; it represents a fundamental change in how biological therapies are procured and valued. Position yourself as an expert who can navigate these complexities to drive efficiency and innovation within your organisation.

For this story, the fields that convert it into pay are Healthcare Management, AI in Pharmaceuticals, Regulatory Affairs and Health Economics — exactly the programmes matched below. The chart shows the indicative salary uplift certified professionals report in each of those fields; every one of them is a click away, from £79, finishing in as few as 20 days.

Indicative salary uplift in the fields matched to this story
Indicative ranges from published continuing-education salary studies, by field — each field is a recommended course below

Matched to this story

Enrol in these
to benefit.

These programmes position you for exactly this shift — online, self-paced, and finishing with a verifiable certificate you can share the day you pass.